ClinicalTrials.gg
Active, not recruitingNCT07220577Updated May 14, 2026

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of GIA632 and Placebo in Atopic Dermatitis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 28 sites in 9 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Dermatitis, Atopic by Novartis — 2 open to participants now, 3 under way, none of them phase 3. Dermatitis, Atopic · Novartis.

Enrollment
21st of 25
34 · median 123
Started
2025
with 1 other
Phase 2
7 of 31
1 open now
Registered
30th of 31
by date

Among the 31 studies in Dermatitis, Atopic by Novartis, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 2, and was the 30th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 31 studies in Dermatitis, Atopic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Dermatitis, Atopic by Novartis, or all of them as a file.
02

Study summary

The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).

Read the detailed description

This is a randomized, placebo-controlled, parallel-group, non-confirmatory, investigator and participant blinded study in adult participants with moderate to severe AD.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Phase 2
  • interventional
  • atopic dermatitis
  • efficacy
  • safety
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able and willing to sign the form
  • Patients with a diagnosis of atopic dermatitis and disease for at least 1 year
  • Moderate to severe atopic dermatitis

Key Exclusion Criteria:

  • Participants with a medical condition or infectious disease (as specified in the protocol)
  • Participants with any clinically significant abnormal clinical laboratory tests, vital signs, physical examination or
  • Participant with any other active inflammatory skin disease would interfere with the appropriate assessment of atopic dermatitis in the opinion of the investigator
  • Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
  • Participants with any clinically unstable disease states that would likely require systemic (e.g., uncontrolled asthma)
  • Women of unless they are using highly effective methods of (failure rate \< 1% per year) while taking study treatment.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    GIA632

    Active treatment arm

    Drug: GIA632

  • Placebo comparator
    Placebo

    Placebo treatment arm

    Other: Placebo

Interventions

  • DrugGIA632

    Active treatment arm

  • OtherPlacebo

    Placebo treatment arm

06

What researchers measure

Primary outcomes

  1. IGA response at Week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baseline

    To assess the efficacy of GIA632 compared to placebo at week 16

    Time frame: Baseline, Week 16

07

Study locations

28 sites
  • Ctr for Dermatology Clinical Res
    Fremont, California 95438, United States
  • Aesthetics Skin Care Dermatologic Surgery
    Rockville, Maryland 20850, United States
  • Care Access Hoboken
    Hoboken, New Jersey 07030, United States
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1202, Bulgaria
  • Novartis Investigative Site
    Sofia, 1618, Bulgaria
  • Novartis Investigative Site
    Toronto, Ontario M5A 3R6, Canada
  • Novartis Investigative Site
    Québec, Quebec G1W 4R4, Canada
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Brno, 602 00, Czechia
  • Novartis Investigative Site
    Prague, 100 34, Czechia
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Martigues, 13500, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Hamburg, 20095, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ipoh, Perak 30450, Malaysia
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Gdansk, 80-546, Poland
  • Novartis Investigative Site
    Torun, 87-100, Poland
  • Novartis Investigative Site
    Warsaw, 00-872, Poland
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Singapore, 308205, Singapore
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 18 months is above that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2025
First posted
Oct 24, 2025
StartActual
Nov 10, 2025
Primary completionEst.
May 17, 2027
CompletionEst.
Sep 6, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07220577
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Nov 10, 2025
Primary completion
May 17, 2027 (estimated)
Completion
Sep 6, 2027 (estimated)
Last update
May 14, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GIA632

Start the discussion